Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/20—Carbocyclic rings
  • C07H15/24—Condensed ring systems having three or more rings
  • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
  • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
  • C07D221/04—Ortho- or peri-condensed ring systems
  • C07D221/18—Ring systems of four or more rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/0803—Compounds with Si-C or Si-Si linkages
  • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
  • C07F7/02—Silicon compounds
  • C07F7/08—Compounds having one or more C—Si linkages
  • C07F7/0803—Compounds with Si-C or Si-Si linkages
  • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
  • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
  • C07H15/20—Carbocyclic rings
  • C07H15/24—Condensed ring systems having three or more rings
  • C07H15/244—Anthraquinone radicals, e.g. sennosides
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
  • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
  • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Definitions

• Daunomycin and adriamycin have been known as anti-neoplastic (and also as antibiotic) compounds for many years.
• novel compounds having anti-tumour activity i.e. compounds according to formula 1 wherein R is -COCH 3 or -C ⁇ C-R 4 ;
• This invention comprises both the separate stereoisomers and mixtures thereof, including racemic mixtures and mixtures of diastereoisomers.
• Dutch patent application 7600075 discloses stereo isomers of the HCI salt of 4-demethoxy daunomycin and the N-trifluoro acetate of 4-demethoxy daunomycin. Furthermore, Dutch patent application 7600075 mentions 1-methoxy daunomycin, 4-demethoxy-2,3-dimethoxy daunomycin and 4-demethoxy-1,4-dimethyl daunomycin and 4-demethoxy-2,3-dimethyl daunomycin, without disclosing physico-chemical properties, details for the preparation and pharmaceutical properties.
• the stereo isomers of 4-demethoxy daunomycin are also described in Anticancer Agents Based on Natural Product Models, edited by J.M. Cassady and J.D.
• DE-A-2,804,099 discloses N-trifluoroacetyl carminomycin and mentions the anti-tumour activity of this compound.
• US-A-4,020,270 mentions N-trifluoroacetyl daunomycin.
• novel compounds of the invention are:
• the cell lines where maintained in a continuous logarithmic culture in Dulbeco's medium supplemented with 10 % fetal calf serum, penicillin (100 IU/ml) and streptomycin (100 ⁇ g/ml).
• the ID 50 values of the above compounds expressed in ng/ml, where determined according to the abovementioned method of van Lambalgen and Lelieveld.
• the ID 50 value is the amount which inhibits 50% of the cell growth.
• N.B. Because in mixtures of diastereoisomers generally one of the diastereoisomers is active and the other is not active or shows very little activity, the activity of the actually or most operative stereoisomer is for HRM11 and HRM15 considerably higher than indicated in the above table, because all compounds were of course examined in the same concentration.
• the present compounds can be synthesized according to several methods which are illustrated in the reaction schemes and preparation examples disclosed hereinafter. It is remarked that many of the intermediate compounds described hereinafter are novel compounds, e.g. the compounds of formulae 15a, 28a, 29a, 36a, 37a, 38, 39, 47, 48, 50, 51, 13a, 27, 33, 44 and 46; these novel compounds also form an aspect of this invention. 1,4,9,10-tetrahydro-5,8-dihydroxy-9,10-dioxo-1,4-ethanoanthracene (9)
• the yellow compound was added to a solution of 20.0 g NaOH in 750 ml water while stirring. The solution was stirred for one hour while compressed air was passed through. The reaction was followed by means of TLC (ethyl acetate:n-hexane, 2:5). After the reaction 35 ml of concentrated HCI (37 %) was added. The precipitated solid compound was filtered off. This red compound was rinsed from the filter with chloroform, whereafter the organic phase was washed with saturated sodium bicarbonate solution. After drying over anhydrous sodium sulphate and evaporating, 20.1 g (85 %, overall 75%) of the compound (9/9a) could be isolated. Melting point 203-204 °C.
• the product was purified by stirring the residue in 200 ml of diethylether for one night. The solid (pale yellow) was filtered off. The filtrate was evaporated and further purified by means of flash column chromatography (column 25 cm, 5 cm ⁇ , eluent ethyl acetate:n-hexane, 2:3). The total yield was 22.2 g (75 %). Melting point 154-158°C.
• reaction mixture was permitted to warm-up slowly to room temperature and 150 ml of a 10 % ammonium chloride solution was added. After 15 minutes 300 ml of water was added and the solution was twice extracted with 300 ml of chloroform. The collected organic fractions were dried over anhydrous sodium sulphate and evaporated after filtration. The residue was dissolved in 60 ml of glacial acetic acid and 3.4 g (7.7 mmol) of lead tetraacetate was added to the solution. After stirring for one night 200 ml of water was added. The red solid which precipitated, was removed by filtration and washed from the filter with 300 ml of chloroform.
• Trimethylsilyl triflate (14.4 mmol) was added to a suspension of 3.55 g of 14 (6.6 mmol) and 20 g of 4 ⁇ molecular sieve in a mixture of 125 ml of methylene chloride and 430 ml of diethylether (both distilled over CaH 2 and sodium, respectively) at -25 ° C and under an argon atmosphere. The solution was stirred at 0°C for one hour until to solution had become clear. Then the solution was cooled to -20 ° C and 2.25 g (5.3 mmol) of 13a, dissolved in 250 ml of methylene chloride, was added.
• reaction mixture was maintained at -20 ° C during the addition and thereafter stirred at -20 ° C during 3 hours.
• the course of the reaction was followed by means of TLC (eluent ethyl acetate:benzene, 1:4).
• TLC eluent ethyl acetate:benzene, 1:4
• the reaction mixture was poured into a solution of 1000 ml of saturated sodium bicarbonate which was stirred vigorously.
• the organic layer was separated and thereafter washed with 1000 ml of water and 1000 ml of a saturated NaCl solution. After drying over sodium sulfate and evaporating, the compounds 15a and 15b were separated by means of column chromatography (eluent ethyl acetate:toluene, 1:16).
• the yield of the yellow/brown product was 30.0 g (91 %).
• the crystals were taken up in a solution of 22.0 g (0.55 mol) of caustic soda in 825 ml of water. During half an hour air was passed through the solution while the solution was stirred. The colour of the solution changed from green to blue. The course of the reaction was followed by means of TLC (ethyl acetate:n-hexane, 2:5). After the reaction 46.2 ml of concentrated HCI (37 %) was added to the solution. The product precipitated as a red solid which was filtered off.
• This compound was dried on a film evaporator (2 mm Hg) and in a vacuum dessicator (over P 2 O 5 ) during at least one night.
• the yield of the red compound (20) was 27.0 g (91 %).
• the overall yield was 83 %. Melting point 239-241 °C.
• reaction mixture was poured into 500 ml of a 5 % NaH 2 PO 4 solution and extracted with 2 x 500 ml of chloroform. The organic phase was dried over anhydrous sodium sulphate and evaporated.
• the crude reaction mixture was purified by means of column chromatography (eluent ethyl acetate:toluene:n-hexane, 1:5:5) and after evaporation stirred into 200 ml of diethylether. The first yellow fraction was the desired product (9.6 g, 50 %). Melting point 136-137 °C.
• reaction mixture was allowed to come slowly to room temperature and 250 ml of a 10 % NH 4 Cl solution was added. After stirring for 15 minutes the solution was diluted with 500 ml of water and extracted with 2 x 500 ml of chloroform. The collected organic fractions were evaporated and the residue was dissolved in 100 ml of glacial acetic acid. To the solution 5.5 g (0.012 mol) of lead tetraacetate was added and the solution was stirred at room temperature for one night. The course of the reaction was followed by means of TLC (ethyl acetate:n-hexane, 2:5). The colour of the solution changed from yellow/red to red. After the reaction the reaction mixture was poured into 400 ml of water.
• TLC ethyl acetate:n-hexane, 2:5
• the mixture was extracted with 2 x 500 ml of chloroform and the collected organic fractions were washed with 500 ml of saturated NaCl solution. After evaporation the residue was dissolved in 100 ml of glacial acetic acid and 5.3 g (12.0 mmol) of lead tetraacetate was added. After stirring for one night the reaction mixture was poured into 400 ml of water and the red solid was filtered off. After rinsing with water the solid was rinsed from the filter with a minimum amount of chloroform and the organic fraction was extracted with successively 100 ml of a saturated NaHCO 3 solution, 2 x 100 ml of water and 200 ml of a saturated NaCl solution.
• the organic phase was washed with 1 x 100 ml of a saturated sodium bicarbonate solution, 100 ml of water and 100 ml of a saturated NaCl solution.
• the product was purified by means of column chromatography (column 15 cm, 2.5 cm ⁇ , eluent ethyl acetate:toluene:n-hexane 1:5:5).
• the yield (34) was 0.45 g (60 %) after recrystallization in diisopropyl ether/methylene chloride. Melting point 180-1 81 °C.
• reaction mixture was maintained at -15°C d urin g the addition and then stirred at -15°C for 4 hours.
• the course of the reaction was followed by means of TLC (eluent ethyl acetate:benzene, 1:4).
• TLC eluent ethyl acetate:benzene, 1:4
• the reaction mixture was poured into a solution of 400 ml of saturated sodium bicarbonate while vigorously stirring.
• the organic layer was separated and then washed with 200 ml of water and 200 ml of a saturated NaCl solution. After drying over anhydrous sodium sulphate and evaporating, the compounds 36a and 36b were separated by means of preparative TLC (eluent ethyl acetate:benzene, 1:4).
• reaction mixture was maintained at -15°C du rin g the addition and then stirred at -15 °C for 3 hours.
• the course of the reaction was followed by means of TLC (eluent ethyl acetate:benzene, 1:4). After all starting material had been converted, the reaction mixture was poured into a solution of 350 ml of saturated sodium bicarbonate while vigorously stirring. The organic layer was separated and then washed with 100 ml of water and 100 ml of a saturated NaCl solution. After drying over anhydrous sodium sulphate and evaporating, compound 47 was purified by means of preparative TLC (eluent methylene chloride:acetone, 9:1). After evaporation of the eluent and treatment with a small amount of n-hexane 0.165 g (42 %) of 47 could be isolated.
• reaction mixture was maintained at -15° C during the addition and then stirred at -15°C for 3 hours.
• TLC eluent ethyl acetate:benzene, 1:4
• the reaction mixture was poured into a solution of 250 ml of saturated sodium bicarbonate while vigorously stirring.
• the organic layer was separated and then washed with 100 ml of water and 100 ml of a saturated NaCl solution.
• compound 50 was purified by means of preparative TLC (eluent methylene chloride:acetone, 9:1). After evaporation of the eluent and treatment with a small amount of n-hexane, 0.126 g (41 %) of 50 could be isolated.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Biochemistry (AREA)
• Biotechnology (AREA)
• Genetics & Genomics (AREA)
• Molecular Biology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Saccharide Compounds (AREA)

Applications Claiming Priority (2)

Publications (2)

Family

ID=19857556

Family Applications (1)

Country Status (5)

Cited By (3)

Family Cites Families (8)

• 1990
  • 1990-08-16 NL NL9001834A patent/NL9001834A/nl not_active Application Discontinuation
• 1991
  • 1991-08-02 EP EP91202015A patent/EP0475473A2/en not_active Withdrawn
  • 1991-08-06 CA CA002048510A patent/CA2048510A1/en not_active Abandoned
  • 1991-08-14 JP JP3288250A patent/JPH04297486A/ja active Pending
• 1992
  • 1992-05-06 US US07/879,737 patent/US5294701A/en not_active Expired - Fee Related

Also Published As

Similar Documents

Legal Events